Back to results
US 10,472,374 B2Granted
ACC inhibitors and uses thereof
AssigneeGilead Apollo, LLC
InventorsSathesh Bhat, Jeremy Robert Greenwood, Geraldine C. Harriman, James Harwood, Craig E. Masse
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.
Claims20
A compound of formula II:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is C1-4 aliphatic;
- R2 is —C(O)R, —C(O)OR, or —OC(O)R;
- each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- R3 is —C(O)N(R)2 or —C(O)OR;
- R4 is an optionally substituted phenyl;
- each of R5 and R5′ is independently —R;
- and
- each of R7 and R7′ is independently hydrogen, —R, or —OR.
6 more elements
A compound of formula III:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is C1-4 aliphatic;
- R2 is —C(O)R, —C(O)OR, or —OC(O)R;
- each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- R3 is —C(O)N(R)2 or —C(O)OR;
- each of R5 and R5′ is independently —R;
- R6 is —R, —C(O)N(R)2, or —C(O)R;
- each R8 is independently selected from halogen, —R, —OR, —SR, —N(R)2 or deuterium;
- and
- n is 0-5.
7 more elements
A compound of formula IV:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is C1-4 aliphatic;
- R2 is —C(O)R, —C(O)OR, or —OC(O)R;
- each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- R3 is —C(O)N(R)2 or —C(O)OR;
- each of R5 and R5′ is independently —R;
- R6 is —R, —C(O)N(R)2, or —C(O)R;
- each R8 is independently selected from halogen, —R, —OR, —SR, —N(R)2 or deuterium;
- and
- n is 0-5.
7 more elements
Dependencies are inferred from the claim text.